The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Long non-coding RNAs in anti-cancer drug resistance
Open accessAbstract
// Qin-nan Chen 1 , Chen-chen Wei 1 , Zhao-xia Wang 1 and Ming Sun 2 1 Department of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, People’s Republic of China 2 Department of Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston, Texas, United States of America Correspondence to: Zhao-Xia Wang, email: // Ming Sun, email: // Keywords : long non-coding RNAs, cancer, drug resistance, chemotherapy, targets Received : May 29, 2016 Accepted : September 16, 2016 Published : October 04, 2016 Abstract Chemotherapy is one of the basic treatments for cancers; however, drug resistance is mainly responsible for the failure of clinical treatment. The mechanism of drug resistance is complicated because of interaction among various factors including drug efflux, DNA damage repair, apoptosis and targets mutation. Long non-coding RNAs (lncRNAs) have been a focus of research in the field of bioscience, and the latest studies have revealed that lncRNAs play essential roles in drug resistance in breast cancer, gastric cancer and lung cancer, et al. Dysregulation of multiple targets and pathways by lncRNAs results in the occurrence of chemoresistance. In this review, we will discuss the mechanisms underlying lncRNA-mediated resistance to chemotherapy and the therapeutic potential of lncRNAs in future cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00121-7 · Cited by 413 · cited 2×
“Nonetheless, increasing proportions of patients eventually develop acquired resistance [80].”
BackgroundDNA double strand break repair and chromosomal translocation: Lessons from animal models
Ferguson, D. O., & Alt, F. W. (2001) · Oncogene · doi:10.1038/sj.onc.1204767 · Cited by 333
Recruitment of Mec1 and Ddc1 Checkpoint Proteins to Double-Strand Breaks Through Distinct Mechanisms
Kondo, T., Wakayama, T., Naiki, T., Matsumoto, K., & Sugimoto, K. (2001) · Science · doi:10.1126/science.1063827 · Cited by 258
Tan, C.-S., Cho, B.-C., & Soo, R. A. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.003 · Cited by 105
Cited by
Exosomes: key players in cancer and potential therapeutic strategy
Dai, J., Su, Y., Zhong, S., Cong, L., Liu, B., Yang, J., Tao, Y., He, Z., Chen, C., & Jiang, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00261-0 · Cited by 1,186
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Emran, T. B., Shahriar, A., Mahmud, A. R., Rahman, T., Abir, M. H., Siddiquee, M. F. R., Ahmed, H., Rahman, N., Nainu, F., Wahyudin, E., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.891652 · Cited by 606
Long Noncoding RNA in Cancer: Wiring Signaling Circuitry
Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488
Role of lncRNA LUCAT1 in cancer
Xing, C., Sun, S.-G., Yue, Z.-Q., & Bai, F. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111158 · Cited by 328
Metadata
- Authors
- Chen, Q.-N., Wei, C.-C., Wang, Z.-X., & Sun, M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-10-04
- Volume
- 8
- Issue
- 1
- Pages
- 1925-1936
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2529378193
- Cited by
- 209
- References
- 4
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long non-coding RNAs in anti-cancer drug resistance. https://app.cochat.ai/papers/10.18632/oncotarget.12461
- The paper
- Chen, Q.-N., Wei, C.-C., Wang, Z.-X., & Sun, M. (2017). Long non-coding RNAs in anti-cancer drug resistance. Oncotarget. https://doi.org/10.18632/oncotarget.12461
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.